On November 9, 2026, Faeth Therapeutics, Inc. (the “Company”) made available a presentation to be used to discuss, among other things, the topline clinical data from the Company’s Phase 2 PIK-201 trial evaluating PIKTOR in patients with advanced endometrial cancer. A copy of the presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.
|
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing multi-node inhibitors of the PI3K/AKT/mTOR pathway for the treatment of cancer. The company’s lead program, PIKTOR, is an investigational all-oral combination of serabelisib and sapanisertib designed to simultaneously inhibit PI3K-alpha, mTORC1, and mTORC2. PIKTOR is currently in Phase 2 clinical trials for advanced endometrial cancer and is planned for Phase 1b trials in HR+/HER2- advanced breast cancer. The company also maintains preclinical programs, including NEAAR and IEM, and intends to explore additional indications such as ovarian and lung cancer. Faeth Therapeutics was co-founded in 2019 and completed a reverse merger with Sensei Biotherapeutics in February 2026, which brought PIKTOR into the combined entity’s pipeline. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Biotechnology | Homepage faeththerapeutics.com |
| Sector Healthcare | IR page investors.faeththerapeutics.com | |
|
Tags
oncology, multi-node inhibition, pi3k/akt/mtor pathway, endometrial cancer, breast cancer, oral therapeutics, clinical-stage, tumor metabolism, signaling pathways, PIKTOR, serabelisib, sapanisertib, NEAAR, IEM, Faeth HoldCo, Faeth Subsidiary, Sensei Biotherapeutics
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 768.551M |
| Market cap (USD) | $ 768.551M |
| P/E | — |
| PEG | — |
| P/BV | 4.77 |
| P/S | — |
| P/OCF | -17.76 |
| P/FCF | -17.76 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -74.0% |
| ROI | -212.5% |
| ROIC | -168.4% |
| Profit margin | — |
| Growth | |
|---|---|
| Revenue growing | — |
| Profits growing | Yes |
| Revenue up 3y | — |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | — |
| Buying back stock | — |
| Diluting (TTM) | — |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 22 |
| Quality score | -55.6% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||
| Borrowings, non-current (USD) | 567,000 | — | — | — | — | — |
| Lease liabilities (USD) | 118,000 | 2.35M | 8.03M | 6.21M | 3.85M | 1.51M |
| Cash and deposits (USD) | 16.6M | 7.16M | 17.8M | 13M | 9.99M | 8.67M |
| Right-of-use assets (USD) | — | — | 5.36M | 4.33M | 2.8M | 1.29M |
| Net debt (borrowings + leases - cash) (USD) | -16M | — | — | — | — | — |
| Cash flow detail | ||||||
| Operating cash flow (USD) | -17.7M | -30.3M | -39M | -32M | -24.7M | -20.5M |
| Purchases of property, plant and equipment (USD) | -1.21M | -2.03M | -321,000 | -180,000 | -146,000 | -16,000 |
| Change in payables (cash effect) (USD) | 335,000 | -1.43M | 2.02M | -2.33M | -445,000 | 233,000 |
| Share buybacks (cash effect) (USD) | — | — | — | -10.4M | — | — |
| Share-based compensation (USD) | 1.49M | 5.66M | 5.81M | 4.45M | 3.14M | 1.27M |
| Free cash flow (OCF - PPE - intangibles) (USD) | -18.9M | -32.3M | -39.3M | -32.2M | -24.8M | -20.5M |
| Income detail | ||||||
| Total comprehensive income (USD) | -20.2M | -37.1M | -49.3M | -33.3M | -30M | -21.1M |
| Comprehensive income to owners (USD) | -20.2M | -37.1M | -49.3M | -33.3M | -30M | -21.1M |
| Reported | Mar 15, 2022 | Mar 15, 2022 | Mar 29, 2023 | Feb 29, 2024 | Mar 28, 2025 | Mar 30, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
• Confirmed Objective Response Rate (ORR) of 33% in efficacy-evaluable patients (12 of 36), and a disease control rate (DCR) of 83%
• Among patients with a PIK3CA mutation, the confirmed ORR was 44% (7 of 16)
• Preliminary Kaplan-Meier estimated median progression-free survival (mPFS) of 7.4 months, with a 6-month PFS rate of 62%
• The combination of PIKTOR with paclitaxel was generally well tolerated, with a treatment-related hyperglycemia rate of 12% (2% Gr. 3) and stomatitis rate of 21% (2% Gr. 3), and a discontinuation rate of 5% due to treatment-related adverse events
• Data support advancement of PIKTOR development into a Phase 3 registrational trial
• Webcast today at 8 a.m.
• FDA granted Fast Track designation to PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer
• Presented preclinical data on PIKTOR in HR+/HER2- breast cancer models at ESMO 2026
AUSTIN, Texas—(BUSINESS WIRE)—November 3, 2026— Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced financial results for the quarter ended September 30, 2026, and highlighted recent corporate accomplishments and 2026 milestones.
“Since our last quarterly update, we presented PK/PD analysis that informed the PIKTOR dose in our Phase 2 PIK-201 trial and received Fast Track designation for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer,” said Anand Parikh, Chief Executive Officer. “The PAM pathway is dysregulated in up to 50% of solid tumors, and feedback reactivation and resistance mutations may limit single-node inhibitors. We designed PIKTOR, an all-oral, multi-node inhibitor, to address those limitations, and we believe it has the potential to give patients a differentiated treatment option.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Jun 18, 2026 | Renamed | SENSEI BIOTHERAPEUTICS, INC. → FAETH THERAPEUTICS, INC. |
| — | Former tickers | SNSE |
ETFs Holding Faeth Therapeutics, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVSC | 0.00% | 4,772 | $ 44.284K | Nov 16, 2026 |